BIS-1: a novel bispecific monoclonal antibody for CEA-expressing carcinoma radioimmunoscintigraphy and radioimmunotherapy.
Parisi
A
A
Biochemical Oncology Laboratory, Sorin Biomedica, Saluggia/VC, Italy.
Bartolazzi
A
A
Bonino
C
C
Camagna
M
M
DeMonte
L B
LB
Lombardi
A
A
Natali
P G
PG
Paganelli
G
G
Tarditi
L
L
Vassarotto
C
C
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D000918:Antibody Specificity; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D002277:Carcinoma / Q000000981:diagnostic imaging / Q000276:immunology* / Q000532:radiotherapy; D005822:Genetic Vectors; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007205:Indium Radioisotopes; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging; D004369:Pentetic Acid; D016719:Radioimmunodetection; D016499:Radioimmunotherapy; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use; D015021:Yttrium Radioisotopes
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D002272:Carcinoembryonic Antigen; D007205:Indium Radioisotopes; D011993:Recombinant Fusion Proteins; D015021:Yttrium Radioisotopes; D004369:Pentetic Acid